RESUMEN
Ipsilateral axillary adenopathy post-COVID mRNA vaccine has been widely reported and guidelines for management have been established. Isolated changes of axillary tail trabecular thickening without associated adenopathy in the breast present a diagnostic dilemma and no official guidelines have thus far been reported. This finding has been reported after COVID mRNA vaccine and has never been reported with any other vaccine. We report on a patient with such changes on screening mammography 1.5 months after the fifth dose of a COVID-mRNA vaccine and 1 week after RSV vaccine. This raises the possibility that such changes can be seen with vaccines other than the COVID mRNA series of vaccines. The main differential diagnosis includes mastitis and inflammatory breast cancer. The transient nature of this finding with spontaneous resolution at diagnostic mammography and the vaccination history helps to establish the diagnosis and exclude breast cancer.
RESUMEN
Deep learning-based mammographic evaluations could noninvasively assess response to breast cancer chemoprevention. We evaluated change in a convolutional neural network-based breast cancer risk model applied to mammograms among women enrolled in SWOG S0812, which randomly assigned 208 premenopausal high-risk women to receive oral vitamin D3 20â000 IU weekly or placebo for 12 months. We applied the convolutional neural network model to mammograms collected at baseline (n = 109), 12 months (n = 97), and 24 months (n = 67) and compared changes in convolutional neural network-based risk score between treatment groups. Change in convolutional neural network-based risk score was not statistically significantly different between vitamin D and placebo groups at 12 months (0.005 vs 0.002, P = .875) or at 24 months (0.020 vs 0.001, P = .563). The findings are consistent with the primary analysis of S0812, which did not demonstrate statistically significant changes in mammographic density with vitamin D supplementation compared with placebo. There is an ongoing need to evaluate biomarkers of response to novel breast cancer chemopreventive agents.
Asunto(s)
Densidad de la Mama , Neoplasias de la Mama , Colecalciferol , Aprendizaje Profundo , Suplementos Dietéticos , Mamografía , Humanos , Femenino , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/prevención & control , Densidad de la Mama/efectos de los fármacos , Persona de Mediana Edad , Colecalciferol/administración & dosificación , Adulto , Vitamina D/administración & dosificación , Premenopausia , Redes Neurales de la Computación , Medición de RiesgoRESUMEN
BACKGROUND: Radial scars/radial sclerosing lesions (RS) are benign breast lesions identified on core needle biopsy (CNB) which can upgrade to malignancy at excision. There is limited data on RS detection and upgrade rates with more sensitive imaging such as magnetic resonance imaging (MRI) and none during their detection for breast cancer workup and its implication on patient treatment decisions. METHODS: A retrospective institutional study of RS diagnosed on CNB between January 2008 and December 2017 was conducted. Clinicopathologic and radiologic features of RS, patient treatment decisions, upgrade rates and long-term follow-up were examined. RESULTS: We identified 133 patients with RS on CNB, of whom 106 opted for surgery for an upgrade rate to malignancy of 1.9%, 2 patients. Radial scar was diagnosed on mammogram in 60%, MRI in 25% and ultrasound in 15% of patients. In this cohort, 32 patients had their RS detected during breast cancer workup (coexistent group) and they were more likely to have their radial scar detected by MRI (60% vs. 14%, P < .001) and undergo more extensive surgery (94% vs. 75%, P = .02). Among the 27 patients electing observation of their RS, only one (3.7%) developed breast cancer. CONCLUSIONS: Our results show an extremely low upgrade rate to malignancy of RS, regardless if there is coexisting breast cancer elsewhere. Despite this, RS still prompted more extensive surgical excisions. The findings do not support excision of RS even among breast cancer patients when identified at a separate site from their cancer.
Asunto(s)
Neoplasias de la Mama , Cicatriz , Imagen por Resonancia Magnética , Mamografía , Humanos , Femenino , Neoplasias de la Mama/patología , Neoplasias de la Mama/diagnóstico por imagen , Biopsia con Aguja Gruesa , Estudios Retrospectivos , Persona de Mediana Edad , Cicatriz/patología , Cicatriz/diagnóstico por imagen , Adulto , Anciano , Mama/patología , Mama/diagnóstico por imagen , Mama/cirugía , Ultrasonografía Mamaria , Estudios de SeguimientoRESUMEN
Purpose To describe the design, conduct, and results of the Breast Multiparametric MRI for prediction of neoadjuvant chemotherapy Response (BMMR2) challenge. Materials and Methods The BMMR2 computational challenge opened on May 28, 2021, and closed on December 21, 2021. The goal of the challenge was to identify image-based markers derived from multiparametric breast MRI, including diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI, along with clinical data for predicting pathologic complete response (pCR) following neoadjuvant treatment. Data included 573 breast MRI studies from 191 women (mean age [±SD], 48.9 years ± 10.56) in the I-SPY 2/American College of Radiology Imaging Network (ACRIN) 6698 trial (ClinicalTrials.gov: NCT01042379). The challenge cohort was split into training (60%) and test (40%) sets, with teams blinded to test set pCR outcomes. Prediction performance was evaluated by area under the receiver operating characteristic curve (AUC) and compared with the benchmark established from the ACRIN 6698 primary analysis. Results Eight teams submitted final predictions. Entries from three teams had point estimators of AUC that were higher than the benchmark performance (AUC, 0.782 [95% CI: 0.670, 0.893], with AUCs of 0.803 [95% CI: 0.702, 0.904], 0.838 [95% CI: 0.748, 0.928], and 0.840 [95% CI: 0.748, 0.932]). A variety of approaches were used, ranging from extraction of individual features to deep learning and artificial intelligence methods, incorporating DCE and DWI alone or in combination. Conclusion The BMMR2 challenge identified several models with high predictive performance, which may further expand the value of multiparametric breast MRI as an early marker of treatment response. Clinical trial registration no. NCT01042379 Keywords: MRI, Breast, Tumor Response Supplemental material is available for this article. © RSNA, 2024.
Asunto(s)
Neoplasias de la Mama , Imágenes de Resonancia Magnética Multiparamétrica , Femenino , Humanos , Persona de Mediana Edad , Inteligencia Artificial , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/tratamiento farmacológico , Imagen por Resonancia Magnética , Terapia Neoadyuvante , Respuesta Patológica Completa , AdultoRESUMEN
Breast cancer remains the leading cause of cancer-related deaths in women worldwide. Current screening regimens and clinical breast cancer risk assessment models use risk factors such as demographics and patient history to guide policy and assess risk. Applications of artificial intelligence methods (AI) such as deep learning (DL) and convolutional neural networks (CNNs) to evaluate individual patient information and imaging showed promise as personalized risk models. We reviewed the current literature for studies related to deep learning and convolutional neural networks with digital mammography for assessing breast cancer risk. We discussed the literature and examined the ongoing and future applications of deep learning techniques in breast cancer risk modeling.
Asunto(s)
Neoplasias de la Mama , Aprendizaje Profundo , Femenino , Humanos , Neoplasias de la Mama/diagnóstico por imagen , Inteligencia Artificial , Mamografía/métodos , Mama/diagnóstico por imagenRESUMEN
Breast ultrasound is a valuable adjunctive tool to mammography in detecting breast cancer, especially in women with dense breasts. Ultrasound also plays an important role in staging breast cancer by assessing axillary lymph nodes. However, its utility is limited by operator dependence, high recall rate, low positive predictive value and low specificity. These limitations present an opportunity for artificial intelligence (AI) to improve diagnostic performance and pioneer novel uses of ultrasound. Research in developing AI for radiology has flourished over the past few years. A subset of AI, deep learning, uses interconnected computational nodes to form a neural network, which extracts complex visual features from image data to train itself into a predictive model. This review summarizes several key studies evaluating AI programs' performance in predicting breast cancer and demonstrates that AI can assist radiologists and address limitations of ultrasound by acting as a decision support tool. This review also touches on how AI programs allow for novel predictive uses of ultrasound, particularly predicting molecular subtypes of breast cancer and response to neoadjuvant chemotherapy, which have the potential to change how breast cancer is managed by providing non-invasive prognostic and treatment data from ultrasound images. Lastly, this review explores how AI programs demonstrate improved diagnostic accuracy in predicting axillary lymph node metastasis. The limitations and future challenges in developing and implementing AI for breast and axillary ultrasound will also be discussed.
Asunto(s)
Inteligencia Artificial , Neoplasias de la Mama , Femenino , Humanos , Ultrasonografía/métodos , Mama/patología , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/patología , Ultrasonografía Mamaria , Ganglios Linfáticos/patologíaRESUMEN
PURPOSE: Deep learning techniques, including convolutional neural networks (CNN), have the potential to improve breast cancer risk prediction compared to traditional risk models. We assessed whether combining a CNN-based mammographic evaluation with clinical factors in the Breast Cancer Surveillance Consortium (BCSC) model improved risk prediction. METHODS: We conducted a retrospective cohort study among 23,467 women, age 35-74, undergoing screening mammography (2014-2018). We extracted electronic health record (EHR) data on risk factors. We identified 121 women who subsequently developed invasive breast cancer at least 1 year after the baseline mammogram. Mammograms were analyzed with a pixel-wise mammographic evaluation using CNN architecture. We used logistic regression models with breast cancer incidence as the outcome and predictors including clinical factors only (BCSC model) or combined with CNN risk score (hybrid model). We compared model prediction performance via area under the receiver operating characteristics curves (AUCs). RESULTS: Mean age was 55.9 years (SD, 9.5) with 9.3% non-Hispanic Black and 36% Hispanic. Our hybrid model did not significantly improve risk prediction compared to the BCSC model (AUC of 0.654 vs 0.624, respectively, p = 0.063). In subgroup analyses, the hybrid model outperformed the BCSC model among non-Hispanic Blacks (AUC 0.845 vs. 0.589; p = 0.026) and Hispanics (AUC 0.650 vs 0.595; p = 0.049). CONCLUSION: We aimed to develop an efficient breast cancer risk assessment method using CNN risk score and clinical factors from the EHR. With future validation in a larger cohort, our CNN model combined with clinical factors may help predict breast cancer risk in a cohort of racially/ethnically diverse women undergoing screening.
Asunto(s)
Neoplasias de la Mama , Femenino , Humanos , Persona de Mediana Edad , Adulto , Anciano , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/epidemiología , Mamografía/métodos , Estudios Retrospectivos , Detección Precoz del Cáncer , Redes Neurales de la ComputaciónRESUMEN
Breast cancer is the most common cancer in women around the world and the fifth leading cause of cancer-related death [...].
RESUMEN
SIGNIFICANCE: Real-time histology can close a variety of gaps in tissue diagnostics. Currently, gross pathology analysis of excised tissue is dependent upon visual inspection and palpation to identify regions of interest for histopathological processing. Such analysis is limited by the variable correlation between macroscopic and microscopic findings. The current standard of care is costly, burdensome, and inefficient. AIM: We are the first to address this gap by introducing optical coherence tomography (OCT) to be integrated in real-time during the pathology grossing process. APPROACH: This is achieved by our high-resolution, ultrahigh-speed, large field-of-view OCT device designed for this clinical application. RESULTS: We demonstrate the feasibility of imaging tissue sections from multiple human organs (breast, prostate, lung, and pancreas) in a clinical gross pathology setting without interrupting standard workflows. CONCLUSIONS: OCT-based real-time histology evaluation holds promise for addressing a gap that has been present for >100 years.
Asunto(s)
Mama , Tomografía de Coherencia Óptica , Mama/diagnóstico por imagen , Humanos , Masculino , Tomografía de Coherencia Óptica/métodosRESUMEN
Breast cancer is the most common cancer among women worldwide. Mammography is the most widely used modality to detect breast cancer. Over the past decade, computer aided detection (CAD) powered by artificial intelligence (AI)/deep learning has shown significant increase in accuracy compared to the traditional CAD. In this review, we aim to summarize the latest developments in the field of AI and mammography and discuss where future progress may lie.
Asunto(s)
Inteligencia Artificial , Neoplasias de la Mama , Neoplasias de la Mama/diagnóstico por imagen , Femenino , Humanos , MamografíaRESUMEN
PURPOSE: We evaluated whether a novel, fully automated convolutional neural network (CNN)-based mammographic evaluation can predict breast cancer relapse among women with operable hormone receptor (HR)-positive breast cancer. METHODS: We conducted a retrospective cohort study among women with stage I-III, HR-positive unilateral breast cancer diagnosed at Columbia University Medical Center from 2007 to 2017, who received adjuvant endocrine therapy and had at least two mammograms (baseline, annual follow-up) of the contralateral unaffected breast for CNN analysis. We extracted demographics, clinicopathologic characteristics, breast cancer treatments, and relapse status from the electronic health record. Our primary endpoint was change in CNN risk score (range, 0-1). We used two-sample t-tests to assess for difference in mean CNN scores between patients who relapsed vs. remained in remission, and conducted Cox regression analyses to assess for association between change in CNN score and breast cancer-free interval (BCFI), adjusting for known prognostic factors. RESULTS: Among 848 women followed for a median of 59 months, there were 67 (7.9%) breast cancer relapses (36 distant, 25 local, 6 new primaries). There was a significant difference in mean absolute change in CNN risk score from baseline to 1-year follow-up between those who relapsed vs. remained in remission (0.001 vs. - 0.022, p = 0.030). After adjustment for prognostic factors, a 0.01 absolute increase in CNN score at 1-year was significantly associated with BCFI, hazard ratio = 1.05 (95% Confidence Interval 1.01-1.09, p = 0.011). CONCLUSION: Short-term change in the CNN-based breast cancer risk model on adjuvant endocrine therapy predicts breast cancer relapse, and warrants further evaluation in prospective studies.
Asunto(s)
Neoplasias de la Mama , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/cirugía , Femenino , Humanos , Recurrencia Local de Neoplasia/diagnóstico por imagen , Redes Neurales de la Computación , Estudios Prospectivos , Estudios RetrospectivosRESUMEN
OBJECTIVE: To investigate the ability of our convolutional neural network (CNN) to predict axillary lymph node metastasis using primary breast cancer ultrasound (US) images. METHODS: In this IRB-approved study, 338 US images (two orthogonal images) from 169 patients from 1/2014-12/2016 were used. Suspicious lymph nodes were seen on US and patients subsequently underwent core-biopsy. 64 patients had metastatic lymph nodes. A custom CNN was utilized on 248 US images from 124 patients in the training dataset and tested on 90 US images from 45 patients. The CNN was implemented entirely of 3 × 3 convolutional kernels and linear layers. The 9 convolutional kernels consisted of 6 residual layers, totaling 12 convolutional layers. Feature maps were down-sampled using strided convolutions. Dropout with a 0.5 keep probability and L2 normalization was utilized. Training was implemented by using the Adam optimizer and a final SoftMax score threshold of 0.5 from the average of raw logits from each pixel was used for two class classification (metastasis or not). RESULTS: Our CNN achieved an AUC of 0.72 (SD ± 0.08) in predicting axillary lymph node metastasis from US images in the testing dataset. The model had an accuracy of 72.6% (SD ± 8.4) with a sensitivity and specificity of 65.5% (SD ± 28.6) and 78.9% (SD ± 15.1) respectively. Our algorithm is available to be shared for research use. (https://github.com/stmutasa/MetUS). CONCLUSION: It's feasible to predict axillary lymph node metastasis from US images using a deep learning technique. This can potentially aid nodal staging in patients with breast cancer.
RESUMEN
PURPOSE: The proliferation of breast epithelial cells increases during the luteal phase of the menstrual cycle, when they are exposed to progesterone, suggesting that ulipristal acetate, a selective progestin-receptor modulator (SPRM), may reduce breast cell proliferation with potential use in breast cancer chemoprevention. METHODS: Women aged 18-39 were randomized 1:1 to ulipristal 10-mg daily or to a combination oral contraceptive (COC) for 84 days. Participants underwent a breast biopsy and breast MRI at baseline and at end of study treatment. Proliferation of breast TDLU cells was evaluated by Ki67 immunohistochemical stain. We evaluated the breast MRIs for background parenchymal enhancement (BPE). All slides and images were masked for outcome evaluation. RESULTS: Twenty-eight treatment-compliant participants completed the study; 25 of whom had evaluable Ki67 results at baseline and on-treatment. From baseline to end of treatment, Ki67 % positivity (Ki67%+) decreased a median of 84% in the ulipristal group (N = 13; 2-sided p (2p) = 0.040) versus a median increase of 8% in the COC group (N = 12; 2p = 0.85). Median BPE scores decreased from 3 to 1 in the ulipristal group (p = 0.008) and did not decrease in the COC group. CONCLUSION: Ulipristal was associated with a major decrease in Ki67%+ and BPE. Ulipristal would warrant further investigation for breast cancer chemoprevention were it not for concerns about its liver toxicity. Novel SPRMs without liver toxicity could provide a new approach to breast cancer chemoprevention. TRIAL REGISTRATION: NCT02922127, 4 October 2016.
Asunto(s)
Neoplasias de la Mama , Leiomioma , Adolescente , Adulto , Neoplasias de la Mama/tratamiento farmacológico , Proliferación Celular , Femenino , Humanos , Norpregnadienos , Progesterona , Receptores de Progesterona , Adulto JovenRESUMEN
RATIONALE AND OBJECTIVES: To evaluate a weakly supervised deep learning approach to breast Magnetic Resonance Imaging (MRI) assessment without pixel level segmentation in order to improve the specificity of breast MRI lesion classification. MATERIALS AND METHODS: In this IRB approved study, the dataset consisted of 278,685 image slices from 438 patients. The weakly supervised network was based on the Resnet-101 architecture. Training was implemented using the Adam optimizer and a final SoftMax score threshold of 0.5 was used for two class classification (malignant or benign). 278,685 image slices were combined into 92,895 3-channel images. 79,871 (85%) images were used for training and validation while 13,024 (15%) images were separated for testing. Of the testing dataset, 11,498 (88%) were benign and 1531 (12%) were malignant. Model performance was assessed. RESULTS: The weakly supervised network achieved an AUC of 0.92 (SD ± 0.03) in distinguishing malignant from benign images. The model had an accuracy of 94.2% (SD ± 3.4) with a sensitivity and specificity of 74.4% (SD ± 8.5) and 95.3% (SD ± 3.3) respectively. CONCLUSION: It is feasible to use a weakly supervised deep learning approach to assess breast MRI images without the need for pixel-by-pixel segmentation yielding a high degree of specificity in lesion classification.
Asunto(s)
Neoplasias de la Mama , Aprendizaje Profundo , Mama , Neoplasias de la Mama/diagnóstico por imagen , Femenino , Humanos , Imagen por Resonancia Magnética/métodos , Sensibilidad y EspecificidadRESUMEN
We developed a deep learning-based super-resolution model for prostate MRI. 2D T2-weighted turbo spin echo (T2w-TSE) images are the core anatomical sequences in a multiparametric MRI (mpMRI) protocol. These images have coarse through-plane resolution, are non-isotropic, and have long acquisition times (approximately 10-15 min). The model we developed aims to preserve high-frequency details that are normally lost after 3D reconstruction. We propose a novel framework for generating isotropic volumes using generative adversarial networks (GAN) from anisotropic 2D T2w-TSE and single-shot fast spin echo (ssFSE) images. The CycleGAN model used in this study allows the unpaired dataset mapping to reconstruct super-resolution (SR) volumes. Fivefold cross-validation was performed. The improvements from patch-to-volume reconstruction (PVR) to SR are 80.17%, 63.77%, and 186% for perceptual index (PI), RMSE, and SSIM, respectively; the improvements from slice-to-volume reconstruction (SVR) to SR are 72.41%, 17.44%, and 7.5% for PI, RMSE, and SSIM, respectively. Five ssFSE cases were used to test for generalizability; the perceptual quality of SR images surpasses the in-plane ssFSE images by 37.5%, with 3.26% improvement in SSIM and a higher RMSE by 7.92%. SR images were quantitatively assessed with radiologist Likert scores. Our isotropic SR volumes are able to reproduce high-frequency detail, maintaining comparable image quality to in-plane TSE images in all planes without sacrificing perceptual accuracy. The SR reconstruction networks were also successfully applied to the ssFSE images, demonstrating that high-quality isotropic volume achieved from ultra-fast acquisition is feasible.
Asunto(s)
Imagenología Tridimensional , Próstata , Humanos , Imagen por Resonancia Magnética , Masculino , Próstata/diagnóstico por imagenRESUMEN
PURPOSE: To utilize a neural architecture search (NAS) approach to develop a convolutional neural network (CNN) method for distinguishing benign and malignant lesions on breast cone-beam CT (BCBCT). METHOD: 165 patients with 114 malignant and 86 benign lesions were collected by two institutions from May 2012 to August 2014. The NAS method autonomously generated a CNN model using one institution's dataset for training (patients/lesions: 71/91) and validation (patients/lesions: 20/23). The model was externally tested on another institution's dataset (patients/lesions: 74/87), and its performance was compared with fine-tuned ResNet-50 models and two breast radiologists who independently read the lesions in the testing dataset without knowing lesion diagnosis. RESULTS: The lesion diameters (mean ± SD) were 18.8 ± 12.9 mm, 22.7 ± 10.5 mm, and 20.0 ± 11.8 mm in the training, validation, and external testing set, respectively. Compared to the best ResNet-50 model, the NAS-generated CNN model performed three times faster and, in the external testing set, achieved a higher (though not statistically different) AUC, with sensitivity (95% CI) and specificity (95% CI) of 0.727, 80% (66-90%), and 60% (42-75%), respectively. Meanwhile, the performances of the NAS-generated CNN and the two radiologists' visual ratings were not statistically different. CONCLUSIONS: Our preliminary results demonstrated that a CNN autonomously generated by NAS performed comparably to pre-trained ResNet models and radiologists in predicting malignant breast lesions on contrast-enhanced BCBCT. In comparison to ResNet, which must be designed by an expert, the NAS approach may be used to automatically generate a deep learning architecture for medical image analysis.
Asunto(s)
Aprendizaje Profundo , Mama , Tomografía Computarizada de Haz Cónico , Humanos , Redes Neurales de la Computación , RadiólogosRESUMEN
Artificial intelligence (AI) in radiology has gained wide interest due to the development of neural network architectures with high performance in computer vision related tasks. As AI based software programs become more integrated into the clinical workflow, radiologists can benefit from better understanding the principles of artificial intelligence. This series aims to explain basic concepts of AI and its applications in medical imaging. In this article, we will review the background of neural network architecture and its application in imaging analysis.
Asunto(s)
Inteligencia Artificial , Radiología , Humanos , Radiografía , Radiólogos , Flujo de TrabajoRESUMEN
INTRODUCTION: We investigated whether our convolutional neural network (CNN)-based breast cancer risk model is modifiable by testing it on women who had undergone risk-reducing chemoprevention treatment. MATERIALS AND METHODS: We conducted a retrospective cohort study of patients diagnosed with atypical hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ at our institution from 2007 to 2015. The clinical characteristics, chemoprevention use, and mammography images were extracted from the electronic health records. We classified two groups according to chemoprevention use. Mammograms were performed at baseline and subsequent follow-up evaluations for input to our CNN risk model. The 2 chemoprevention groups were compared for the risk score change from baseline to follow-up. The change categories included stayed high risk, stayed low risk, increased from low to high risk, and decreased from high to low risk. Unordered polytomous regression models were used for statistical analysis, with P < .05 considered statistically significant. RESULTS: Of 541 patients, 184 (34%) had undergone chemoprevention treatment (group 1) and 357 (66%) had not (group 2). Using our CNN breast cancer risk score, significantly more women in group 1 had shown a decrease in breast cancer risk compared with group 2 (33.7% vs. 22.9%; P < .01). Significantly fewer women in group 1 had an increase in breast cancer risk compared with group 2 (11.4% vs. 20.2%; P < .01). On multivariate analysis, an increase in breast cancer risk predicted by our model correlated negatively with the use of chemoprevention treatment (P = .02). CONCLUSIONS: Our CNN-based breast cancer risk score is modifiable with potential utility in assessing the efficacy of known chemoprevention agents and testing new chemoprevention strategies.
Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/patología , Carcinoma/diagnóstico por imagen , Carcinoma/patología , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/prevención & control , Carcinoma/prevención & control , Quimioprevención , Femenino , Humanos , Mamografía , Persona de Mediana Edad , Redes Neurales de la Computación , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Medición de RiesgoRESUMEN
Non-invasive diagnosis of breast cancer is still challenging due to the low specificity of the imaging modalities that calls for unnecessary biopsies. The diagnostic accuracy can be improved by assessing the breast tissue mechanical properties associated with pathological changes. Harmonic motion imaging (HMI) is an elasticity imaging technique that uses acoustic radiation force to evaluate the localized mechanical properties of the underlying tissue. Herein, we studied the in vivo feasibility of a clinical HMI system to differentiate breast tumors based on their relative HMI displacements, in human subjects. We performed HMI scans in 10 female subjects with breast masses: five benign and five malignant masses. Results revealed that both benign and malignant masses were stiffer than the surrounding tissues. However, malignant tumors underwent lower mean HMI displacement (1.1 ± 0.5 µm) compared to benign tumors (3.6 ± 1.5 µm) and the adjacent non-cancerous tissue (6.4 ± 2.5 µm), which allowed to differentiate between tumor types. Additionally, the excised breast specimens of the same patients (n = 5) were imaged post-surgically, where there was an excellent agreement between the in vivo and ex vivo findings, confirmed with histology. Higher displacement contrast between cancerous and non-cancerous tissue was found ex vivo, potentially due to the lower nonlinearity in the elastic properties of ex vivo tissue. This preliminary study lays the foundation for the potential complementary application of HMI in clinical practice in conjunction with the B-mode to classify suspicious breast masses.